Pluri Inc.

Stocks

Real-time Estimate Cboe BZX 12:45:58 31/10/2026 am IST			5-day change	1st Jan Change
1.220 ^USD	+1.67%		+23.86%	-58.99%

03:06pm	Pluri Inc. - Special Call
27/10	Pluri Insider Bought Shares Worth $1,250,001, According to a Recent SEC Filing	MT

Published on 10/30/2026 at 03:06 pm IST

S&P Capital IQ

Presenter Speech
Unknown Executive (Executives)

[Audio Gap]

will follow the formal presentation. As a reminder, this webinar is being recorded. Yaky, please.

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

03:06pm	Pluri Inc. - Special Call
27/10	Pluri Insider Bought Shares Worth $1,250,001, According to a Recent SEC Filing	MT
26/10	Pluri Inc. and Zeo Scientifix, Inc. Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine	CI
19/10	Pluri Inc. announced that it expects to receive $1.250001 million in funding from Chutzpah Holdings Limited	CI
11/09	Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
10/09	Pluri Inc. Auditor Raises 'Going Concern' Doubt	CI
28/07	Cellav Health and Aesthetics Ltd Completes Regulatory Registration of Regenativo+ in the UK	CI
23/06	Pluri Inc. Announces Board and Board Committee Changes	CI
02/06	Cellav Health and Aesthetics Ltd Completes Development and U.S. Cosmetic Product Listings of Regenativo+ and Placento+	CI
02/06	Pluri Biotech Ltd., Pluristem Gmbh, and Pluri Inc. Remain in Constructive Discussions with European Investment Bank Regarding EUR 20 Million Loan	CI
15/05	Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
26/03	Pluri Inc. announced that it expects to receive $2.5 million in funding	CI
13/02	Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
22/01	Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials	CI
22/12	Pluri, Inc. Announces Expansion of Its Manufacturing Agreement with Remedy Cell Ltd	CI

Duration

Period

Sector